Novo Nordisk is debuting its first-Super Bowl commercial to promote its newly launched once-daily Wegovy pill, an oral formulation of semaglutide for adults with obesity or overweight with related medical conditions.

The campaign, titled ‘A New Way to Wegovy,’ marks a notable shift for both the company and the broader obesity drug market. While injectable GLP-1 therapies have reshaped treatment and demand over the past several years, the introduction of an oral option, and its placement in a mass-market advertising moment, signals Novo Nordisk’s push to expand the addressable population beyond early adopters comfortable with injections.¹

What is the commercial about?

The commercial released on the morning of February 6^th and uses both humor and celebrity appearances to challenge the notion that weight-loss medications represent “the easy way out.” Novo says that this reframes obesity as a chronic disease that often requires medical intervention alongside diet and exercise.¹ The campaign is also intended to reduce stigma and encourage more open conversations about weight management between patients and healthcare providers.

The ad features a cast including Kenan Thompson, DJ Khaled, Danielle Brooks, Ana Gasteyer, John C. Reilly, and Danny Trejo, reinforcing the campaign’s effort to normalize medical treatment for weight loss. “I know what it's like to go hard in the gym, eat clean, stay disciplined put in that work every single day, but still not see the results you want,” said DJ Khaled. “When you're trying to reach your goals and you're looking for something more, having an option like Wegovy pill – that's powerful.”

“Millions of people may be curious about trying a medicine to help manage their weight, but are sitting on the sidelines, waiting for an option that works for them. That's why we're proud to feature Wegovy pill in the ad. We're focused on expanding access to real, affordable FDA-approved medicine backed by science,” said Ed Cinca, senior vice president of Marketing & Patient Solutions at Novo Nordisk. “We chose to show up at the big game because it gives us a rare chance to speak to so many people at once to cut through clutter and start honest conversations about weight for people who want to take a step toward better health.”

What is the Wegovy pill?

The Wegovy pill is the first oral GLP-1 medicine approved in the U.S. for obesity. In addition to weight management, it is also indicated to reduce the risk of major adverse cardiovascular events, including heart attack and stroke, in adults with overweight or obesity and established cardiovascular disease, an increasingly important differentiator as payers scrutinize long-term value and outcomes. The pill recently became available for U.S. patients earlier in January this year.

Novo Nordisk is pairing its big game commercial launch with broad commercial availability and aggressive access strategies, as the company announced that the Wegovy pill is now available in over 70,000 U.S. pharmacies, including major retail chains, as well as select telehealth providers.¹ For self-pay patients with a prescription, the starting dose is being offered at $149 per month, while commercially insured patients may pay as little as $25 per month through savings programs.

Sources

1. Novo Nordisk takes the field at the big game, putting Wegovy pill in consumers' hands Novo Nordisk February 6, 2026 https://www.prnewswire.com/news-releases/novo-nordisk-takes-the-field-at-the-big-game-putting-wegovy-pill-in-consumers-hands-302680855.html
2. Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Novo Nordisk January 5, 2026 https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html
3. Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management Novo Nordisk December 22, 2025 https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472